GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Debt-to-Asset

Viatris (WBO:MYL) Debt-to-Asset : 0.39 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Viatris Debt-to-Asset?

Viatris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1,850 Mil. Viatris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €14,996 Mil. Viatris's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €43,728 Mil. Viatris's debt to asset for the quarter that ended in Dec. 2023 was 0.39.

Viatris Debt-to-Asset Historical Data

The historical data trend for Viatris's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Debt-to-Asset Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.43 0.43 0.39 0.39

Viatris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.39 0.39 0.38 0.39

Competitive Comparison of Viatris's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Viatris's Debt-to-Asset falls into.


Viatris Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Viatris's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1850.231 + 14996.159) / 43727.603
=0.39

Viatris's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1850.231 + 14996.159) / 43727.603
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris  (WBO:MYL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Viatris Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Viatris's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (WBO:MYL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Debt-to-Asset
Comparable Companies
NBIX CTLT ELAN ITCI ALKS PRGO LNTH PBH ALVO AMPH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 XSWX:SDZ SZSE:000538 BOM:500124
Traded in Other Exchanges
VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Website
https://www.viatris.com
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines